GYNAZOLE-1
Clinical safety rating: caution
Comprehensive clinical and safety monograph for GYNAZOLE-1 (GYNAZOLE-1).
Butoconazole nitrate, an imidazole antifungal agent, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing fungal cell membrane permeability.
| Metabolism | Minimal systemic absorption; primarily metabolized in the liver via oxidation and conjugation pathways. |
| Excretion | Primarily as unchanged drug in feces via biliary elimination; <1% excreted renally as metabolites. |
| Half-life | Terminal elimination half-life is approximately 6-7 days after intravaginal administration, reflecting slow absorption from the vaginal mucosa and prolonged retention in tissues. |
| Protein binding | Approximately 99% bound, primarily to albumin. |
| Volume of Distribution | Systemic Vd not well defined due to minimal absorption; after IV administration in animals, Vd is approximately 1.3 L/kg, suggesting extensive tissue distribution. |
| Bioavailability | Intravaginal: approximately 2-5% systemically absorbed. |
| Onset of Action | Clinical effect (symptom relief) typically begins within 1-2 days after a single intravaginal dose. |
| Duration of Action | A single dose provides therapeutic effect for up to 7 days, with clinical cure rates maintained through 28 days. |
| Molecular Weight | Tinidazole: 247.27 Da; Tioconazole: 387.2 Da |
One 100 mg vaginal ovule inserted intravaginally as a single dose.
| Dosage form | CREAM |
| Renal impairment | No adjustment required for renal impairment. |
| Liver impairment | No adjustment required for hepatic impairment. |
| Pediatric use | Not recommended for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | Same as adult dose; no specific adjustments required. |
| 1st trimester | Category C: Adverse effects in animal studies; no adequate human studies. Use only if potential benefit justifies risk. |
| 2nd trimester | Category C: Limited data; avoid use unless clearly needed. |
| 3rd trimester | Category C: Avoid near term due to theoretical risk of kernicterus (sulfonamide component). |
Clinical note
Comprehensive clinical and safety monograph for GYNAZOLE-1 (GYNAZOLE-1).
| Placental transfer | Both components (tinidazole and tioconazole) cross the placenta. Tinidazole achieves fetal concentrations 30-100% of maternal serum. |
| Breastfeeding | Limited excretion in breast milk; concentrations are low. However, due to sulfonamide component, theoretical risk of kernicterus in neonates with G6PD deficiency or hyperbilirubinemia. Caution advised; monitor infant for jaundice. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to nitroimidazoles or imidazolesPregnancy (Category C) - cautionBreastfeeding in neonates with G6PD deficiency or jaundice
| Precautions | For intravaginal use only, Not for ophthalmic or oral use, Discontinue if hypersensitivity occurs, May reduce efficacy of latex condoms and diaphragms, Use caution in patients with known sensitivity to imidazole antifungals |
| Food/Dietary | No known food interactions. Avoid alcohol as it may worsen vaginal irritation in some patients. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating |
| L3 (Moderately Safe) |
| Teratogenic Risk | GYNAZOLE-1 (butoconazole nitrate 2% vaginal cream, single dose) is a topical azole antifungal. Systemic absorption is minimal (approximately 1.7% of dose). Based on limited human data and animal studies, no increased risk of major birth defects or miscarriage has been observed with topical azole use during pregnancy. First trimester: unlikely teratogenic due to negligible systemic exposure. Second and third trimesters: no fetal risks identified with topical use. Category C (FDA) due to lack of adequate human studies, but widely used in pregnancy when indicated. |
| Fetal Monitoring | No specific monitoring required beyond standard prenatal care. Monitor for local irritation or allergic reaction. If used in pregnancy, assess for treatment failure or recurrence. Fetal monitoring not needed due to minimal systemic exposure. |
| Fertility Effects | No known adverse effects on fertility. Vaginal candidiasis treatment may improve fertility by resolving local infection. No hormonal or reproductive system interference. |
| GYNAZOLE-1 (butoconazole nitrate 2% vaginal cream) is a single-dose azole antifungal for vulvovaginal candidiasis. It is equally effective as 7-day clotrimazole regimens. Avoid in patients with known hypersensitivity to azoles. Use during pregnancy only if clearly needed (category C). May weaken latex condoms and diaphragms. |
| Patient Advice | Insert one full applicator of cream into the vagina at bedtime. · Do not use tampons, douche, or have sexual intercourse during treatment. · Wash hands before and after application. · Complete the single dose even if symptoms improve. · Avoid using condoms or diaphragms for 72 hours after dose as the cream can damage latex. · Contact doctor if symptoms persist beyond 3 days or if fever, chills, or foul-smelling discharge occur. |